6.7.14. Guideline for non-metastatic castrate-resistant disease. RecommendationStrength ratingOffer apalutamide, darolutamide or enzalutamide to patients with M0 CRPC and a high risk of developing metastasis (PSA-DT < ten months) to prolong time to metastases and overall survival.Strong 